Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Elekta AB ( ($SE:EKTA.B) ) just unveiled an update.
Elekta has invited analysts and investors to a conference call and webcast on March 5 at 9:00 a.m. CET to present its third-quarter 2025/26 financial results, with the interim report scheduled for release earlier that morning. The session, led by President and CEO Jakob Just-Bomholt alongside the CFO, underscores the company’s ongoing engagement with capital markets and provides stakeholders an opportunity to assess operational performance and strategic direction in the competitive radiation therapy sector.
The most recent analyst rating on ($SE:EKTA.B) stock is a Hold with a SEK51.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
More about Elekta AB
Elekta AB is a Stockholm-headquartered medical technology company specializing in precision radiation therapy for cancer treatment. With around 4,500 employees and offices in more than 40 countries, it develops outcome-driven, cost-efficient oncology solutions and is listed on Nasdaq Stockholm, serving healthcare providers focused on advanced cancer care.
Average Trading Volume: 1,332,737
Technical Sentiment Signal: Hold
Current Market Cap: SEK20.77B
See more data about EKTA.B stock on TipRanks’ Stock Analysis page.